Eligibility Criteria For Pancreatic Cancer Clinical Trial

Eligibility criteria for the CSGO-HBP-027 clinical trial investigating neoadjuvant chemotherapy with and without radiotherapy for resectable pancreatic ductal adenocarcinoma. The trial is designed to enroll 200 patients across multiple centers in Japan. The dataset includes criteria for patient selection, randomization, and treatment protocols.

Use Cases

• Analyze patient selection criteria to identify key inclusion and exclusion variables for trial design.
• Compare treatment arm protocols (GS vs. GS-RT) using the randomization ratio and radiotherapy dose details.
• Assess endpoint definitions, such as overall survival and R0 resection rate, for outcome measurement planning.

Strengths

• Data originates from a registered, multicenter randomized phase II/III clinical trial (jRCTs051250150).
• Clear definition of primary (overall survival) and secondary endpoints (resection rate, R0 resection rate).
• Specific treatment protocols are detailed, including radiotherapy dose (50.4 Gy in 28 fractions).

Limitations

• The dataset is very small at 13.5 KB, indicating it contains only protocol criteria, not patient-level outcome data.
• Sample size is limited to the planned enrollment of 200 patients from the trial.
• Geographic coverage is restricted to Japan, limiting generalizability to other populations.

Provenance

Source

figshare, authored by Yoshito Tomimaru.

Collection Method

Documented eligibility criteria from the CSGO-HBP-027 clinical trial protocol.

Time Range

Covers the trial protocol period.

Freshness

Last updated March 2026.

Geography

Japan.